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ABSTRACT 
AN OPEN LABELLED RANDOMIZED CLINICAL TRIAL OF FLUOXETINE 
VERSUS DAPOXETINE TREATMENT AMONG MEN WITH PREMATURE 
EJACULATION AND ITS EFFECT ON MARITAL SATISFACTION 
INTRODUCTION:  Premature ejaculation (PE) causes reduces sexual satisfaction and 
quality of life. Both Selective Serotonin Re-uptake Inhibitor Fluoxetine and Dapoxetine have 
been used in treatment of PE. Fluoxetine is used as off-label treatment meanwhile Dapoxetine 
is the first SSRI specifically designed for PE that has a short half-life and few side effects. 
OBJECTIVES: To compare the PE symptoms score and marital satisfaction score between 
Fluoxetine and Dapoxetine groups. 
METHODS: In this open labelled randomized clinical trial, 44 participants aged between 18 
and 64 with PEDT score of ≥ 9 from the Primary Care clinic of Hospital USM, Kelantan 
Malaysia were recruited and randomized into two groups; Fluoxetine Group (FG) and 
Dapoxetine Group (DG). They were prescribed with either daily oral Fluoxetine 20mg or 
Dapoxetine 30mg on demand twice weekly for 8 weeks. PE symptoms were measured using 
the Premature Ejaculation Diagnostics Tool (PEDT) score and marital satisfaction score were 
measured using the Dyadic Satisfaction-Dyadic Adjustment Scale (DS-DAS) score. 
Measurements were made at baseline and at the 8
th
 week (post intervention). 
RESULTS: In FG and DG, 22 and 21 participants completed the study, respectively. PEDT 
scores reduced significantly within both groups [from 11.41 to 5.45 (P<0.001) within FG and 
from 13.43 to 3.10 (P<0.001) within the DG]. At the 8
th
 week follow-up, PEDT scores was 
observed to be were lower in DG (6.03 vs. 2.49, P<0.001) after adjustment of the baseline 
PEDT score. Significantly increased DS-DAS scores were observed in both groups [from 
xii 
 
34.50 to 40.68 (P<0.001) within FG and from 36.57 to 44.33, (P<0.001) within DG] with no 
significant difference in DS-DAS scores at the end of study (41.13 vs. 43.86, P=0.055) after 
adjustment of the baseline DS-DAS score. 
CONCLUSIONS: Reduction in PE symptoms was observed for both groups. At 8 weeks, PE 
symptoms among participants on Dapoxetine were significantly lower compared to the 
participants on Fluoxetine group at 8 weeks. Treatment of PE with either Fluoxetine or 
Dapoxetine reduces symptoms of PE and improves marital satisfaction. 
 
Keywords: Premature ejaculation, Fluoxetine, Dapoxetine, Marital satisfaction, PEDT, DS-
DAS
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ABSTRAK 
PERCUBAAN KLINIKAL SECARA RAWAK DI ANTARA RAWATAN  UBAT 
FLUOXETINE DAN DAPOXETINE DIKALANGAN PARA LELAKI YANG 
MENGHIDAP EJAKULASI PRAMATANG DAN KESANNYA KE ATAS 
KEPUASAN PERKAHWINAN 
PENGENALAN: Ejakulasi pramatang menyebabkan penurunan kepuasan seksual dan 
kualiti hidup. Ubatan Perencat Pengambilan Semula Serotonin Terpilih Fluoxetine dan 
Dapoxetine telah digunakan untuk rawatan ejakulasi pramatang. Fluoxetine digunakan 
sebagai rawatan ‘off-label’ manakala Dapoxetine adalah ubat pertama Perencat Pengambilan 
Semula Serotonin Terpilih dengan jangka masa hayat pendek dihasilkan secara spesifik untuk 
kegunaan rawatan ejakulasi pramatang dengan jangka hayat pendek dan kurang kesan 
sampingan. 
OBJEKTIF: Untuk membandingkan skor gejala ejakulasi pramatang dan skor kepuasan 
perkahwinan di antara kumpulan Fluoxetine dan Dapoxetine.  
KAEDAH: Kajian ini merupakan dua cabang percubaan klinikal secara rawak dengan 
seramai 44 orang subjek di antara umur 18 hingga 64 tahun dengan skor PEDT ≥ 9 dari 
Klinik Rawatan Primer, Hospital USM, Kelantan Malaysia telah dipilih dan dirawakkan 
kepada dua kumpulan iaitu kumpulan Fluoxetine (FG) dan kumpulan Dapoxetine (DG). 
Mereka telah menerima secara teratur Tablet Fluoxetine 20mg sekali sehari atau Tablet 
Dapoxetine 30mg diambil apabila perlu secara maksimum sebanyak 2 kali seminggu masing-
masing untuk setiap kumpulan selama 8 minggu. Gejala ejakulasi pramatang telah diukur 
menggunakan skor PEDT dan skor kepuasan perkahwinan telah diukur menggunakan skor 
DS-DAS. Penilaian telah dilakukan pada permulaan dan selepas 8 minggu intervensi. 
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KEPUTUSAN: Dalam kumpulan Fluoxetine (FG) dan kumpulan Dapoxetine (DG), seramai 
22 dan 21 subjek telah menamatkan kajian dengan sempurna. Skor PEDT telah menunjukkan 
penurunan secara signifikan dalam setiap kumpulan (dari 11.41 kepada 5.45), (P<0.001) iaitu 
dalam kumpulan Fluoxetine (FG) dan (dari 13.43 kepada 3.10), (P<0.001) iaitu dalam 
kumpulan Dapoxetine (DG). Selepas 8 minggu, skor PEDT telah diperhatikan lebih rendah 
dalam kumpulan Dapoxetine (6.03 vs. 2.49, P< 0.001) selepas penyelarasan nilai permulaan 
skor PEDT. Peningkatan secara signifikan untuk skor DS-DAS telah diperhatikan untuk 
kedua- dua kumpulan iaitu dari 34.50 kepada 40.68, (P< 0.001) dalam kumpulan Fluoxetine 
dan dari 36.57 kepada 44.43, (P< 0.001) dalam kumpulan Dapoxetine dengan tiada perbezaan  
dalam skor DS-DAS selepas kajian, (41.13 vs. 43.86, P=0.055) selepas penyelarasan nilai 
permulaan skor DS-DAS. 
RUMUSAN: Penurunan gejala ejakulasi pramatang telah diperhatikan untuk kedua- dua 
kumpulan. Pada 8 minggu, gejala ejakulasi pramatang dikalangan pesakit dalam rawatan 
Dapoxetine signifikan lebih menurun berbanding dalam rawatan Fluoxetine pada 8 minggu. 
Rawatan ejakulasi pramatang sama ada Fluoxetine atau Dapoxetine mengurangkan gejala 
ejakulasi pramatang dan meningkatkan nilai perkahwinan. 
 
Kata kunci: Ejakulasi pramatang, Fluoxetine, Dapoxetine, Kepuasan perkahwinan, PEDT, 
DS-DAS
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CHAPTER 1: INTRODUCTION 
 
Premature ejaculation (PE) is the most common male sexual dysfunction worldwide resulting 
in reduced sexual satisfaction and quality of life for men and their partners (1-4). By literature 
revealed that the prevalence of PE in Asia Pacific region was 31% (5) meanwhile, in a 
primary care settings was 20.3% (6).  
Men with PE was postulated may have decreased levels of serotonin (7, 8). For many years, 
selective serotonin re uptake inhibitor (SSRI) had been proven to treat PE (9) and were 
expected to significantly increased the geometric mean of intravaginal ejaculatory latency 
time (IELT) by 2.6 to 13.2 fold (10).  
The clinical concept and management of PE have developed gradually in the recent years. 
Daily long acting SSRI Fluoxetine is regarded as a safe and effective treatment for PE (11) 
with 7 fold increment of ejaculatory interval one week after starting treatment (11) and is 
widely used as off-label treatment in Malaysia. Meanwhile, on demand short acting SSRI, 
Dapoxetine, is the first SSRI with a short half-life is effective and well tolerated in the 
treatment of PE (12). It is justified to compare the effectiveness of both medications in the 
treatment of PE that so far has been poorly investigated. 
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CHAPTER 2:  LITERATURE REVIEW 
 
2.1: PREMATURE EJACULATION: DEFINITION 
Premature ejaculation was documented in Greek literature as ‘ejaculation ante portas’ and 
first appeared in medical literature in 1887 by Gross as a “rapid ejaculation”. Diagnostic 
criteria for PE have been proposed by a wide range of organisations. Many observational 
studies (9, 13) and clinical trials (13-15) have used the diagnostic criteria of the Diagnostic 
and Statistical Manual of Mental Disorders, 4
th
 Edition (DSM-4-TR) 2000 by American 
Psychiatric Association.  
The recent latest updated 5
th
 Edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5TM) published in May, 2013 by American Psychiatric Association (14) 
defines PE as “a persistent or recurrent pattern of ejaculation occurring during partnered 
sexual activity within approximately 1 minute following vaginal penetration and before the 
individual wishes it, must have been present for at least 6 months and must be experienced on 
almost all or all occasions of sexual activity, causes clinically significant distress in the 
individual and sexual dysfunction is not better explained by a non- sexual, mental disorder or 
as a consequence of severe relationship distress or other significant stressors and is not 
attributable to the effects of a substance/ medication or another medical condition”.  
Alternatively, the revised definition of PE defined by International Society for Sexual 
Medicine (ISSM) in 2014 as “an ejaculation which always or nearly always occurs prior to 
or within about 1 minute of vaginal penetration and inability to delay ejaculation on all or 
nearly all vaginal penetration, and negative personal consequences, such as distress, bother, 
frustration and/ or the avoidance of sexual intimacy”(15). 
3 
 
Similarly, American Urological Association (AUA) has defined PE as ejaculation that occurs 
sooner than desired, either before or shortly after penetration causing distress to either one or 
both partners (16). 
 
2.2: PREMATURE EJACULATION: PATHOPHYSIOLOGY & PATHOGENESIS 
Ejaculation is a biphasic process, consisting of emission and expulsion processes which 
involve distinct anatomical structures (17). The emission phase is centrally controlled and 
involves the epididymis, vas deferens, seminal vesicles, prostate gland, prostatic urethra, and 
bladder neck (9). During the phase, seminal fluid is secreted from the prostate and seminal 
vesicles, the smooth muscles of the seminal tract contract to transport the ejaculate and sperm 
is ejected into the posterior urethra (17). The expulsion phase occurs through a spinal cord 
reflex and involves the bladder neck, urethra, and pelvic striated muscles to forcefully 
advance semen via the urethral meatus (9).  
Current evidence also suggests that PE is a psychoneuroendocrinological phenomenon (18). 
The process of ejaculation is centrally regulated by interconnected cerebral sensory areas and 
motor centres involving a range of neurotransmitters including serotonin, dopamine, and 
oxytocin (9). Evidence postulates that serotonin and specific serotonin receptor subtypes play 
a key role in ejaculation that involved in the process of delaying ejaculation (17). It has been 
suggested that PE may be related with the presence of low synaptic concentration of 
serotonin in regions of the central nervous system that modulate ejaculation, high probably 
because of variations in serotonin receptor sensitivity (19). 
PE is related with lower level of serotonin concentration and, basically, the men with PE may 
have decreased levels of serotonin (7, 8). Serotonergic pathways are involved in central 
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inhibitory control of ejaculation (20). The reduction of serotonin levels correlates well with a 
shorter ejaculatory response (10). Serotonin is considered to be the key inhibitory 
neurotransmitter involved in the control of ejaculation. The synaptic cleft serotonin is 
regulated by a transporter re-uptake system and several auto-receptors.  Generally, the SSRI’s 
restrain the serotonin transporter system, enhancing levels of serotonin in the synaptic cleft 
(8). 
The International Society for Sexual Medicine (ISSM) has stated that ejaculation is centrally 
mediated basically by both the serotonergic and dopaminergic systems (21). Animal studies 
have clearly revealed that stimulation of the serotonin receptor facilitates ejaculation (21).  
 
2.3: PREMATURE EJACULATION: EPIDEMIOLOGY 
It is the most common male sexual disorder worldwide resulting in reduced sexual 
satisfaction and quality of life followed by erectile dysfunction (ED) and decreased libido 
(hypoactive sexual desire disorder) (1).  The strong association between PE and impaired 
quality of life warrants recognition of PE as a significant public health concern (22).  
Previous studies revealed that PE is the most common male sexual complaint of up to 30% 
(2). It is more prevalent than ED in Asia Pacific region for about 31% and 20%, respectively 
(5). The Premature Ejaculation Prevalence and Attitude (PEPA) study revealed that the 
prevalence of PE among men between the ages of 18 to 70 years old was 22.7% (23). A study 
conducted in a primary care settings has demonstrated the prevalence of PE was 20.3% (6).  
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2.4: IMPACTS OF PREMATURE EJACULATION 
PE has been related with a wide range of negative psychological effects in men and their 
female partners. The men with PE should be monitored closely to ensure that their treatment 
and sexual satisfaction are preserved (24). Many aspects of the lives of both men and their 
female partners are impacted with PE, however only 9% of them seek consultation (25, 26). 
Consequently, it has a greater negative impact on quality of life for the both partner 
significantly (3, 4). However, most men feel reluctant to discuss PE disorder despite its 
psychological, emotional, and relational implications (24). 
Symond et. al demonstrated that PE negatively impact on self-confidence and future or 
current marital relationships among men (27). It also resulted in marital dissatisfaction with 
sexual intercourse and increased emotional distress for both couples (28).  
Previous literature also revealed that PE significantly affects men and their female partners 
and may prevent single men forming new partner relationships (29). However, men with PE 
are reluctant to get treatment although they may be encouraged to do so with their partner's 
support in the presence of effective treatment’s available (29). 
PE can have a significant adverse effect on the quality of life for men and his partner and may 
potentially leads to psychological distress, poor inter-personal relationships, diminished self- 
esteem, anxiety, ED, and reduced libido (24). Literature also showed that the men affected 
with PE have poor control over ejaculation (90%), personal distress (75%), sexual 
dissatisfaction (78%) and inter-personal difficulties (50%) (4).  
The European Urology study in 2007 demonstrated that men with PE reported experiencing a 
high level of personal distress, a low level of personal and partner satisfaction with sexual 
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relationship and less sexual activity than men without PE. Most men with underlying PE 
believed that increasing their IELT would increase their sexual relationship value (30). 
PE also significantly affects the partner (13). About 38.3% of women reported poor 
satisfaction with sexual intercourse with men with PE compared to 90% with partners 
without PE (5). The couples affected by PE have poor relationship problems, a reduced 
quality of life and had low sexual satisfaction (1).  
Almost 40% of the women revealed that they were more satisfied in prior relationships with 
men who did not have PE and around 20% of them stated that PE was a major sexual 
problem (31). Barnes revealed that the relatively short IELT caused emotional distress to 
female partners (32). However, men with PE experienced more distress and sexual 
dissatisfaction than did their couples (33). 
A recent study in 2014 revealed a significant link between ejaculatory control and marital 
dissatisfaction. Those women reporting less sexual problems considered ejaculatory control 
as more important and showed more PE related distress (31). 
Singaporean men are aware of their partner’s satisfaction and motivates them to seek opinion 
in health facilities (34). From this study, the concern of PE is slightly greater than ED 
problem and a significant number of men expressed concern about both issues. It concluded 
that PE results in negative personal distresses like frustration, lowered self-esteem, and 
decreased partner satisfaction. 
The cross cultural differences in women's perception of PE study involving 3 countries which 
was Mexico, South Korea and Italy, demonstrated that lack of control was the most 
commonly reported reason for distress, short-latency, and lack of control over ejaculation. 
7 
 
Mexico showed the highest rates of previous relationship break-ups secondary to PE and 
Italian women showed the lowest relationship satisfaction (35). 
 
2.5: GENERAL ASSESSMENT OF PREMATURE EJACULATION 
PE is usually a self-reported diagnosis. The diagnosis is made wholly by the clinical 
assessment of the sexual history of the patient. Despite of proper history that fulfilled the 
DSM-5 TR criteria for the diagnosis of PE, a simplified tool which is ‘Premature ejaculation 
diagnostic tool’ (PEDT) is a brief, multi-dimensional, and validated instrument for proper 
guidance in the diagnosis of PE. It covers five salient issues for PE which includes control 
over ejaculation, frequency, minimal sexual stimulation, distress, and interpersonal 
relationship. The development and validation of PEDT has resulted in a new, user-friendly 
and brief self-report questionnaire for implement in clinical trials to facilitate and diagnose 
men with PE disorder (36). The questionnaire was translated to Malay language with 
satisfactory construct validity and internal consistency reliability (Cronbach alpha) of 0.86 
(37). 
Intravaginal ejaculation latency time (IELT) is defined as the time between the start of 
vaginal intromission and the start of intravaginal ejaculation. It is used in clinical trials study 
to assess the amount of SSRI induced ejaculation delay in men with PE (38). However, IELT 
is one factor used to diagnose and treat condition of PE.   
Ideally, the suggested IELT for diagnosing PE has varied in the literature from 1 to 2 min or 
less. However, a recently published studies by Patrick et. al on a large community based 
population study of men and their partners might give the best estimate of 'normal' 
ejaculatory latency to date. From this study, the investigators found that the median IELT 
8 
 
recorded using a partner- held stopwatch was 7.3 minutes for men without PE, whereas men 
with PE had a median IELT of 1.8 minutes (39, 40). The multinational population survey of 
IELT involving 500 couples from Netherlands, United Kingdom, Spain, Turkey, and United 
States revealed that the overall median value of IELT was 5.4 minutes (38). 
 
2.6: GENERAL ASSESSMENT OF MARITAL SATISFACTION 
Dyadic Satisfaction Dyadic Adjustment Scale (DS-DAS) is a questionnaire that contains 10 
items on marital satisfaction with test- retest internal consistency reliability of 0.94 (41). It is 
simple, brief, and user friendly. The validated Malay version of DS-DAS questionnaire had 
internal consistency reliability of 0.7 (42). 
Other tools for assessment of marital satisfaction are Evaluation and Nurturing Relationship 
Issues, Communication and Happiness (ENRICH) marital satisfaction scale and Female 
Sexual Function Index (FSFI). ENRICH marital satisfaction scale is a 125 items 
questionnaire for married couples that examines communication, conflict resolution, role 
relationship, financial management, expectations, sexual relationship, personality 
compatibility, marital satisfaction and other personal beliefs related to marriage. Meanwhile, 
FSFI had 19 for assessing the key dimensions of sexual function in women (43). The 
validated Malay version of FSFI questionnaire was conducted (44). However, the FSFI 
questionnaire only measure sexual functioning in women and not marital satisfaction in men.  
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2.7: SELECTIVE SEROTONIN RE-UPTAKE INHIBITOR (SSRI) IN PREMATURE 
EJACULATION 
SSRI had been proven to treat PE since 1994 by Waldinger et. al started with long acting 
SSRI’s Paroxetine (9). SSRI, which were developed to treat depression and other psychiatric 
disorders are increasingly used as off-label treatment for PE (10). The most well studied 
SSRI on PE such as Paroxetine, Sertraline, and Fluoxetine drugs (10). Systematic review and 
meta-analysis study had demonstrated that SSRIs were presumed to increase significantly the 
geometric mean IELT by 2.6 to 13.2 fold (10). Daily dosing showed more effectiveness than 
on demand dosing among conventional SSRI (10).  
The well-known adverse effects associated with SSRI are neurological issues, bodyweight 
changes, dermatological reactions, anti-cholinergic side effects, drug-drug reaction, and 
sexual side effects such as ED and loss of sexual drive (45). Minor adverse event are 
encountered and usually start in the initial week of treatment, slowly disappear within 2- 3 
weeks include fatigue, yawning, mild nausea, loose stool, and perspiration (46). Reduced 
libido or mild ED is not reported frequently (46). All the known SSRI except Fluvoxamine 
could lengthen IELT and could improve the sexual satisfaction of both the men and their 
partners, but their side effects should be caution (47).  
A meta-analysis studies of all SSRI and Clomipramine demonstrated a similar efficacy for 
the daily treatment with the serotonergic antidepressants Paroxetine hemihydrate, 
Clomipramine, Sertraline, and Fluoxetine (48). It is recommended that daily SSRI are the 
first choice of treatment in PE (16). Commonly used SSRIs are Paroxetine (20-40 mg/day), 
Sertraline (50-100 mg/day), and Fluoxetine (20-40 mg/day) (46).  
The American Urological Association 2004 guideline stated that the serotonergic 
antidepressants Paroxetine, Sertraline, Fluoxetine, Clomipramine, and the topical Lidocaine 
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Prilocaine cream are among the effective treatment options. Advanced effective therapy like 
on demand Dapoxetine and on demand  PSD502, a metered dose aerosol containing 
Lidocaine and Prilocaine are effective agents in management of PE (49). However, the 
efficacies of the current SSRI are moderate in the treatment of PE and they have not been 
officially accepted by the FDA. Therefore, new agent of short acting SSRI Dapoxetine needs 
to be further considered and evaluated (50). 
Recently, with the new era of short acting SSRI Dapoxetine was specially developed for 
treatment of PE with on demand dosing to minimize the incidence of side effects with regular 
dosing of daily long acting SSRI (12). 
 
2.8: NOVEL TREATMENT OF FLUOXETINE IN PREMATURE EJACULATION 
Despite treating psychiatric problems, long acting SSRI Fluoxetine also can be effective as 
the treatment of PE as minimal dose as 20mg daily and had shown same effectiveness with 
other doses (46). It is understood that as demonstrated by a physiological study, Fluoxetine 
increased the penile sensory threshold without changing the amplitudes and latencies of 
sacral evoked response and cortical somato-sensory evoked potential (51). Among the SSRIs, 
only Fluoxetine and Citalopram have active metabolites that inhibit serotonin reuptake 
system, however the active metabolite of Fluoxetine which is Norfluoxetine is slightly more 
potent than its parent compound (52). The elimination half-lives of Fluoxetine and 
Norfluoxetine are longer than for any of the other SSRIs, which could be advantages in cases 
of a missed dose or non-compliance to medication (52). 
Kara et. al in 1996 revealed Fluoxetine regarded as a safe and effective treatment in 
managing people with PE (11). Furthermore, Manasia et. al in 2003 for the men with PE, 
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90mg of Fluoxetine weekly may be graded as an effective agent and safe treatment for the 
men with underlying PE significantly (53). A double blind placebo controlled study of 
Fluoxetine showed a 7- fold increment of ejaculatory interval 1 week after initiating of the 
treatment post intervention (11). By other literature also demonstrated that Fluoxetine 
significantly improved ejaculation (54).  
In addition, another study had shown that Fluoxetine is more superior compared to Tri-cyclic 
antidepressant Clomipramine in term of well tolerability of the adverse effect (55). However, 
the relatively large study, using a validated questionnaire confirmed similar useful effect 
between Fluoxetine, Paroxetine, and Escitalopram in increase IELT (56).  
Biochemically, Fluoxetine has a long half-life of around 1 to 4 days and its active metabolite 
Norfluoxetine has an even longer half-life of 2 to 4 weeks to achieve it steady state 
concentration (57). For this reason, when used in treatment of PE, long acting SSRI is 
prescribed with chronic daily dosing schedule to ensure its proven efficacy that achieved the 
therapeutic level (58, 59). 
There had been reported of several common adverse events related with Fluoxetine such as 
nausea, headache, and insomnia (11). Fluoxetine is effective agent for the treatment of PE, 
however with daily chronic dosing was end up with high dropout rate by 6 month, half of 
them defaulted treatment and subsequently by 1 year, three quarters quit the treatment due to 
intolerable adverse effect at the end (45). 
The American Urological Association (AUA) recommends SSRIs of Fluoxetine, Paroxetine, 
Sertraline, and the Tricyclic antidepressant Clomipramine as first line treatment of PE (16). 
The Fluoxetine dose ranging from 5 to 20 mg/day was reported to be more effective in 
delaying ejaculation and enhancing patient or partner satisfaction than placebo (60). 
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Majority of government hospital in Malaysia used long acting SSRI Fluoxetine as the first 
line treatment as off-label for PE for it potentially side effect of delaying ejaculation and its 
highly available in government health facilities despite widely used in treating psychiatric 
problem mainly depression. 
 
2.9: NOVEL TREATMENT OF DAPOXETINE IN PREMATURE EJACULATION 
Dapoxetine is the first SSRI with a short half-life specifically formulated for the treatment of 
PE (12). From the recent research trials had shown its effectiveness and generally well 
tolerated (12). It quickly enhances the synaptic levels of serotonin improving PE parameters 
(17, 20).  
The most common adverse events reported with Dapoxetine are nausea, dizziness, and 
headache in only 2% of the participants (4). Adverse events associated with Dapoxetine are 
dose dependant and tend to be non-severe and non-serious (4). According to recent result 
from clinical trial, the side effects are usually mild to moderate and are more frequent at the 
first dose taken or in the first week of treatment (4). As the men continue taking Dapoxetine 
over the time, the side effects decrease in frequency and the severity (4).  
Dapoxetine works effectively on the first dose and should be taken at least 6 doses or four 
weeks before we can evaluating the individual response and its efficacy improves with 
continued use (4). Dapoxetine is well tolerated based on robust clinical trials involving over 
6000 men with PE demonstrated it improved of control over ejaculation and improved sexual 
satisfaction significantly (4).  
It has significant better safety profile in mood and related adverse events, neurocognitive 
related effects, urogenital system, and sexual function compared to the alternate oral therapy 
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group in the study population (61). By current literature regarding Dapoxetine, the results of 
post-marketing observational study demonstrated that Dapoxetine for treatment of PE has a 
good safety profile and low prevalence of treatment emergent adverse events (62).  
Dapoxetine is the first and only short acting SSRI drug that specifically formulated for the 
treatment of PE and now approved in over 50 countries including Malaysia. It significantly 
improves all measures of PE parameters including improved the control over ejaculation, 
increase sexual satisfaction, decreases inter-personal difficulty, decreases personal distress 
and improves IELT significantly. The discontinuation rate among patients are was around 1.7 
to 5.3% only (63). 
Dapoxetine is quickly absorbed and rapidly cleared avoiding accumulation in the body and 
for this reason it is uniquely suitable for on demand dosing with less side effect encountered 
(1, 17). It is well absorbed and highly eliminated faster than other types of long acting SSRI 
such as Paroxetine, Sertraline and Fluoxetine by it short acting half- life in nature (64). 
 
2.10: OTHER ALTERNATIVES TREATMENT IN PREMATURE EJACULATION 
Other well-known antidepressants known to cause anorgasmia and delayed ejaculation have 
been assessed in the management of PE such as long acting SSRI Paroxetine and Sertraline, 
and also tri- cyclic antidepressant Clomipramine (16). However, previous studies have 
demonstrated that Nefazodone, Citalopram, and Fluvoxamine are ineffective agents for the 
PE treatment and may be more preferable than other SSRI for treatment of depression in men 
not wanting ejaculatory impairment (16). 
Daily administration of Paroxetine have been shown to increase IELT (16). Study done also 
revealed the extent of ejaculation delay induced by Paroxetine was significantly higher than 
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acupuncture (65). Meanwhile Sertraline either given in daily doses of 25, 50, 100 or 200 mg 
or situationally in doses of 50 mg has been shown to increase IELT (16). Higher doses may 
increase efficacy but logic suggests that higher doses may be associated with increased risk of 
ED and decreased libido (16). Clomipramine is a tricyclic antidepressant with SSRI effects 
has improved IELT and other parameters of PE when prescribed at doses of 25 and 50 
mg/day or 25 mg 4 to 24 hours prior to sexual intercourse (16).  
Besides, topical anaesthetic agents like Lidocaine and Prilocaine also may be applied to the 
penis prior to performing sexual intercourse to delay ejaculation process (16). Intracorporal 
injection of a vasoactive agent such as ‘Alprostadil’ and the administration of Viagra 
therapies are effective in the management of ED have been found to increase IELT in patients 
with PE in a few small studies only (16). 
 
2.11: JUSTIFICATIONS OF THE STUDY 
PE is the most frequent male disorder sexual complaint and it has a serious negative impact 
on quality of life for both couples. A study done in a primary care setting in Malaysia showed 
a prevalence of 20.3% (6). By the previous literatures reported that both Fluoxetine and 
Dapoxetine treatments are effective agents in the management of PE. Based on the above 
recent literatures, it is justified to compare the effectiveness of both drugs in the treatment of 
PE that so far has been poorly investigated.  
Dapoxetine is the only short acting SSRI’s drug licenced for the treatment of PE. The 
advantage of treatment encountered when patient can only take it on demand basis compared 
to long acting SSRI’s Fluoxetine treatment where daily doses are compulsory to reach it 
therapeutic level and likely end up with poor adherence with medication at the end. As the 
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new option of treatment is available, it is important to demonstrate the outcome of both drug 
treatments either on demand or daily dosage among men with PE’s symptoms in our regional 
population. 
Long acting SSRI’s mainly Fluoxetine are used increasingly as off-label treatment of PE and 
have greater well known adverse effects compared to short acting SSRI Dapoxetine but it 
well accepted as the first line treatment in government hospital especially in our country 
Malaysia. Meanwhile, Dapoxetine is the only short acting SSRI drug that licensed for 
treatment of PE and proven efficacy, but there is no studies done previously comparing it 
with the regular dosage of long acting SSRI Fluoxetine apart of Paroxetine. Furthermore, this 
study also indirectly will further reflect the effectiveness of both Fluoxetine and Dapoxetine 
treatments on marital satisfaction in men with PE disorder. 
The present study is important to determine the efficacy and safety of Fluoxetine and 
Dapoxetine in the treatment of PE. Asian population are preferred to consume traditional 
products rather than modern drugs for the health benefits. The study also will offer new 
insight and generated new ideas of using both drugs. It is hoped that the data obtained will be 
used as one of the holistic approach which should be targeted in the formulation of a national 
PE intervention programme with comparing 2 common drugs. 
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CHAPTER 3:  OBJECTIVES 
 
3.1: GENERAL OBJECTIVE 
1- To compare the PE symptoms and marital satisfaction between FG and DG among men 
with PE who attended the Primary Care clinic, Hospital USM, Kelantan. 
 
3.2: SPECIFIC OBJECTIVES 
1- To compare the PE symptoms score between baseline and 8 weeks in FG and DG.  
2- To compare the marital satisfaction score between baseline and 8 weeks in FG and DG 
3- To compare the PE symptoms score between FG and DG at baseline and 8 weeks post 
intervention. 
4- To compare the marital satisfaction score between FG and DG at baseline and 8 weeks 
post intervention. 
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3.3: RESEARCH HYPOTHESES 
1- There are significant differences in PE symptoms score between baseline and 8 weeks in 
FG and DG.  
2- There are significant differences in marital satisfaction score between baseline and 8 
weeks in FG and DG. 
3- There are significant differences in PE symptoms score between FG and DG at baseline 
and 8 weeks post intervention. 
4- There are significant differences in marital satisfaction score between FG and DG at 
baseline and 8 weeks post intervention. 
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3.4: OPERATIONAL DEFINITION 
(1) Premature ejaculation: A participant with PEDT score ≥ 9 (included PE and probable PE). 
(2): Marital satisfaction: Mental state that reflects the perceived benefits and cost of marriage 
to the participant. 
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CHAPTER 4:  METHODOLOGY 
 
4.1: STUDY DESIGN 
Two-armed open labelled randomized clinical trial 
 
4.2:  STUDY DURATION 
July 2013 until June 2015 (24 months) 
 
4.3: STUDY POPULATION 
Reference population: All men with PE who attended the Primary Care clinic, Hospital 
USM. 
Source population: All men with PE who attended the Primary Care clinic, Hospital USM.  
Study population: All men with PE who fulfilled the study criteria. 
Sampling frames: Men with PE who attended the Primary Care clinic, Hospital USM from 
July 2013 until June 2015. 
. 
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4.4: INCLUSION & EXCLUSION CRITERIA 
4.4 (1) INCLUSION CRITERIA: 
 1- Age:  18 to 64 years old  
2- Married at least 6 months 
3- Sexually active (at least 2 times/ week) 
4- PEDT score ≥ 9 
 
4.4 (2) EXCLUSION CRITERIA: 
1- Currently on SSRI’s drug. 
2- Contraindicated to SSRI’s drug (66):  
 Allergic/hypersensitivity to drugs 
 Pathological cardiac condition: Heart failure, conduction failures, significant 
ischaemic and valvular heart disease and history of syncopal attack 
 Currently on monoamine oxidase inhibitor and serotonergic drug 
 Drugs that have strong effect on CYP3A4 
 Moderate to severe hepatic impairment 
 Uncontrolled epilepsy 
 Raised intraocular pressure or angle closure glaucoma 
 History of mental problems such as mania/depression/bipolar/schizophrenia 
3- Illiterate.  
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4.5: LICENSE AND REGISTRATION OF DRUGS 
Both types of drugs already registered and licensed under Ministry of Health (MOH) 
Malaysia. The medication was taken orally once daily preferably on night time with or 
without meal. 
Drugs:  
1- Tablet Fluoxetine HCL 20mg (FDA- 1977)    :  MAL 08010743AC 
2- Tablet Dapoxetine HCL 30mg (FDA- 2004)   :  MAL 20102027AR  
 
 
4.6: INVESTIGATIONAL PRODUCT-DOSES AND TREATMENT REGIME 
4.6 (1): FLUOXETINE 20MG 
Low dose tablet form of Fluoxetine (20mg) daily was given regularly up to 8 weeks. The 
medication can be taken at any time with or without meal (52). 
 
4.6 (2): DAPOXETINE 30MG 
Low dose tablet form of Dapoxetine (30mg) was given regularly maximum twice weekly 1 to 
3 hours before performing sexual intercourse with a full glass of water for 8 weeks (66). It 
can be taken with or without meal.  
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4.7: SAMPLE SIZE CALCULATION 
The sample size was calculated for all the objectives of the study and the number of study 
participants required was selected based on the biggest sample size calculation. 
For objective 1 and objective 2, sample size were calculated using sample size calculation for 
comparison of 2 dependent means. The calculation however, yield lower sample size 
compared to between groups comparison as for objective 3 and objective 4. 
The sample size calculation for the comparison of PE symptoms score and marital 
satisfaction score between the two groups at baseline and 8 weeks were calculated using 
‘Power and Sample size calculation software’ that comparing 2 independent means. 
Objective 3:  
α = level of significance was 0.05 
 = 20% (power of study 80%) 
σ = Standard deviation of premature ejaculation based on the PEDT score was 4.4 (67) 
δ = Detectable different in PEDT score between Fluoxetine and Dapoxetine groups based on 
expert opinion = 4 
m = Ratio of Fluoxetine to Dapoxetine group was 1 
The minimum sample size was 20 participants per group. After considering 10% of non-
response rate; the calculated sample size was 22 participants per group. 
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Objective 4 
α = level of significance was 0.05 
 = 20% (power of study 80%) 
σ = Standard deviation of DS-DAS was 7.2 (41) 
δ = Detectable different in DS-DAS score between Fluoxetine and Dapoxetine groups based 
on expert opinion= 1 
m = Ratio of Fluoxetine to Dapoxetine group was 1 
The minimum sample size was 18 participants per group. After considering 10% of non-
response rate; the calculated sample size was 20 participants per group. 
 
Objective 3 yielded the biggest sample size (n=22). Hence, it was taken as the sample size of 
the study, (n=22 per group). 
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4.8: RANDOMIZATION METHOD 
Participants were randomly allocated to receive either Fluoxetine or Dapoxetine medication 
after completing an informed consent. The generated block randomization sequences were 
performed using randomization software (https://www.randomizer.org/). Concealment and 
allocation was done using sealed envelopes. This procedure was performed to avoid selection 
bias and confounders during recruitment process for both interventions. Execution of 
randomization as generated with no modification or adaptation. 
 
BLINDING  
This study is an open labelled randomized clinical trial in which both participant and 
investigator know which treatment is being allocated and administered. Blinding is not 
feasible owing to the nature of taking regular daily Fluoxetine and on demand Dapoxetine.  
 
 
 
 
 
 
 
 
 
